Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.

Giubellino A, Shankavaram U, Bullova P, Schovanek J, Zhang Y, Shen M, Patel N, Elkahloun A, Lee MJ, Trepel J, Ferrer M, Pacak K.

PLoS One. 2014 Apr 3;9(4):e90458. doi: 10.1371/journal.pone.0090458. eCollection 2014.

2.

Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Matro J, Giubellino A, Pacak K.

Horm Metab Res. 2013 Feb;45(2):147-53. doi: 10.1055/s-0032-1331211. Epub 2013 Jan 15. Review.

3.

Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.

Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL.

Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014 Jan 3.

4.

Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.

Qin N, de Cubas AA, Garcia-Martin R, Richter S, Peitzsch M, Menschikowski M, Lenders JW, Timmers HJ, Mannelli M, Opocher G, Economopoulou M, Siegert G, Chavakis T, Pacak K, Robledo M, Eisenhofer G.

Int J Cancer. 2014 Nov 1;135(9):2054-64. doi: 10.1002/ijc.28868. Epub 2014 Apr 7.

5.

Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.

Powers JF, Korgaonkar PG, Fliedner S, Giubellino A, Pacak K, Sahagian GG, Tischler AS.

PLoS One. 2014 Feb 7;9(2):e87807. doi: 10.1371/journal.pone.0087807. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e92492.

6.

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.

Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ.

J Clin Endocrinol Metab. 2009 Jan;94(1):5-9. doi: 10.1210/jc.2008-1836. Epub 2008 Nov 11.

PMID:
19001511
7.

Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.

King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K.

J Clin Oncol. 2011 Nov 1;29(31):4137-42. doi: 10.1200/JCO.2011.34.6353. Epub 2011 Oct 3.

8.

Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.

Schovanek J, Bullova P, Tayem Y, Giubellino A, Wesley R, Lendvai N, Nölting S, Kopacek J, Frysak Z, Pommier Y, Kummar S, Pacak K.

Endocrinology. 2015 Nov;156(11):4094-104. doi: 10.1210/en.2015-1476. Epub 2015 Aug 12.

9.

Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.

Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP.

Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51. doi: 10.1111/cen.12542. Epub 2014 Jul 30. Review.

PMID:
25041164
10.

Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile.

Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS.

Neuroscience. 2007 Jul 29;147(4):928-37. Epub 2007 Jun 20.

PMID:
17582688
11.

DNA flow cytometry in pheochromocytoma and paraganglioma.

Jung WH, Yang WI, Park C, Choi IJ.

Yonsei Med J. 1992 Sep;33(3):249-57.

12.

Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.

Welander J, Andreasson A, Brauckhoff M, Bäckdahl M, Larsson C, Gimm O, Söderkvist P.

Endocr Relat Cancer. 2014 Jun;21(3):495-504. doi: 10.1530/ERC-13-0384. Epub 2014 Apr 16.

13.

DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.

de Cubas AA, Korpershoek E, Inglada-Pérez L, Letouzé E, Currás-Freixes M, Fernández AF, Comino-Méndez I, Schiavi F, Mancikova V, Eisenhofer G, Mannelli M, Opocher G, Timmers H, Beuschlein F, de Krijger R, Cascon A, Rodríguez-Antona C, Fraga MF, Favier J, Gimenez-Roqueplo AP, Robledo M.

Clin Cancer Res. 2015 Jul 1;21(13):3020-30. doi: 10.1158/1078-0432.CCR-14-2804. Epub 2015 Mar 30.

14.

MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.

Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stålberg P, Khanafshar E, Shibru D, Duh QY, Clark OH, Kebebew E, Gill AJ, Clifton-Bligh R, Robinson BG, Benn DE, Sidhu SB.

Endocr Relat Cancer. 2010 Aug 16;17(3):835-46. doi: 10.1677/ERC-10-0142. Print 2010 Sep.

15.

Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature.

Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, Solis DC, Perera SM, Huynh TT, Lubensky IA, Tischler AS, Kvetnansky R, Alesci S, Morris JC, Pacak K.

Clin Exp Metastasis. 2009;26(3):239-50. doi: 10.1007/s10585-009-9236-0. Epub 2009 Jan 25.

16.

Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.

Guo Z, Lloyd RV.

Adv Anat Pathol. 2015 Sep;22(5):283-93. doi: 10.1097/PAP.0000000000000086. Review.

PMID:
26262510
17.

Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis.

Bugalho MJ, Silva AL, Domingues R.

Fam Cancer. 2015 Dec;14(4):603-7. doi: 10.1007/s10689-015-9818-8.

PMID:
26071763
18.

The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.

Bizama C, Benavente F, Salvatierra E, Gutiérrez-Moraga A, Espinoza JA, Fernández EA, Roa I, Mazzolini G, Sagredo EA, Gidekel M, Podhajcer OL.

Int J Cancer. 2014 Feb 15;134(4):755-64. doi: 10.1002/ijc.28405. Epub 2013 Aug 29.

19.

Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma.

Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T, Sugisawa C, Yamada M, Otuka Y, Kurihara I, Sugano K, Nakane M, Fukuuchi A, Kitamoto T, Saito J, Nishikawa T, Naruse M.

Endocr Relat Cancer. 2014 May 6;21(3):L13-6. doi: 10.1530/ERC-13-0530. Print 2014 Jun. No abstract available.

20.

Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.

Burnichon N, Buffet A, Gimenez-Roqueplo AP.

Curr Opin Oncol. 2016 Jan;28(1):5-10. doi: 10.1097/CCO.0000000000000249. Review.

Supplemental Content

Support Center